MedTrace Logo

Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

NCT01054781 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2012-09-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

DRUG

Rituximab

1st cycle R+R-CHOP 2-8th cycle R-CHOP

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • WonSeog Kim, M.D., PhD. · Samsung Medical Center, Seoul, Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054781 on ClinicalTrials.gov